Know Cancer

forgot password

Phase I/II Study of Intratumoral Injection of CPG 7909, A TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides

Phase 1/Phase 2
18 Years
Not Enrolling
Mycosis Fungoides

Thank you

Trial Information

Phase I/II Study of Intratumoral Injection of CPG 7909, A TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides

Inclusion Criteria:

- Biopsy confirmed mycosis fungoides of stage IB-IVA. Patients must
have failed or have been intolerant of at least 2 topical or one systemic treatment.

- Patients must have at least one site of disease that is accessible for intratumoral
injection of CpG percutaneously, and the second site to follow treatment response.

- 18 years of age or older

- Karnofsky Performance Status (KPS) of > 70.

- Adequate bone marrow function: WBC>4,000uL, hemoglobin > 10g/dL; platelet count
>100,000/mm^3; ANC> 1000.

- Adequate hepatic function: bilirubin <= 1.5 mg/dL; SGOT/SGPT<3xupper limit of normal

- Adequate renal function: serum creatinine <= 2.0mg/dL.

- Required wash out periods for prior therapy:

- Topical therapy: 2 weeks

- Chemotherapy: 4 weeks

- Radiotherapy (including photo therapy): 4 weeks

- Systemic biological therapy for mycosis fungoides: 4 weeks

- Other investigational therapy: 4weeks

- Patients of reproductive potential and their partners must agree to use an effective
(>90% reliability) form of contraception during the study and for 4 weeks following
the last study drug administration.

- Women of reproductive potential must have negative urine pregnancy test.

- Life expectancy greater than 4 months.

- Able to comply with the treatment schedule.

Exclusion Criteria:- Pre-existing autoimmune or antibody mediated disease including:
systemic lupus, erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's
syndrome, autoimmune thrombocytopenia, but excluding controlled thyroid disease, or the
presence of autoantibodies without clinical autoimmune disease.

- Known history of human immunodeficiency virus (HIV), hepatitis B or hepatitis C
(active, prior treatment, or both).

- Patients with active infection or with a fever >38.50 C within three days prior to
the first scheduled treatment.

- CNS metastases

- Prior malignancy (active within 5 years of screening) except basal cell or completely
excised non-invasive squamous cell carcinoma of the skin, or in situ squamous cell
carcinoma of the cervix.

- Prior treatment with CpG.

- History of allergic reactions attributed to compounds of similar composition to CPG

- Current anticoagulant therapy (ASA<= 325mg/day allowed).

- Significant cardiovascular disease (i.e. NYHA class 3 congestive heart failure;
myocardial infarction with the past 6 months; unstable angina; coronary angioplasty
with the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias).

- Pregnant or lactating.

- Any other medical history, including laboratory results, deemed by the investigator
to be likely to interfere with their participation in the study, or to interfere with
the interpretation of the results.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety and efficacy of intratumoral CpG injections combined with local radiation

Outcome Time Frame:


Safety Issue:


Principal Investigator

Ronald Levy

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University


United States: Food and Drug Administration

Study ID:




Start Date:

March 2005

Completion Date:

Related Keywords:

  • Mycosis Fungoides
  • Mycoses
  • Mycosis Fungoides